PV QA 4 - Poster Viewing Q&A 4
TU_38_3700 - The Efficacy of Accelerated Radiation Therapy By Simultaneous Integrate Boosting Combined with Chemotherapy for Patients with Limited-Stage Small Cell Lung Cancer
Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3
The Efficacy of Accelerated Radiation Therapy By Simultaneous Integrate Boosting Combined with Chemotherapy for Patients with Limited-Stage Small Cell Lung Cancer
M. Su1, J. You2, J. CUI2, M. Song2, L. Jiang2, D. LI2, H. Yu2, R. Yu2, and A. SHI2; 1Department of Radiation Oncology, Peking University First Hospital, Beijing, China, 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Purpose/Objective(s): To evaluate the efficacy of accelerated twice-daily radiotherapy by simultaneous integrate boosting combined with chemotherapy for patients with limited-stage small cell lung cancer. Materials/Methods: We retrospectively analyzed a total of 33 patients with limited-stage small cell lung cancer from December 2012 through September 2017. Patients were treated with accelerated radiotherapy. The therapeutic gross tumor volume (GTV) received a dose of 54Gy delivered in 30 fractions of 1.8 Gy twice daily, and the planning target volume (PTV) was treated with 45 Gy at 1.5 Gy twice-daily in 30 fractions. Concurrent chemotherapy is etoposide plus cisplatin, consisted of 100 mg of etoposide per square meter of body-surface area on days 1, 2, and 3 and 75 mg of cisplatin per square meter of body-surface area on day 1 for 3-week cycle. Results: The median age of 33 patients involved was 55 years (range, 30 to 68) .The median follow up time was 16.7months(range, 2.8 to 31.8). The one-year and two-year PFS was 76.0% and 51.4%, the one-year and two-year OS was 81.7% and 63.5%, and the the one-year and two-year locoregional failure-free survival rate was 89.1% and 76.1%, respectively. 14 patients (42.4%) experienced grade 2 acute esophagitis, while 1 patient（3.0%）experienced grade 3 acute esophagitis. 2 patients（6.1%）developed Grade 2 pneumonitis. No patient developed Grade 3 or higher radiation-related pneumonia. 11(33.3%) and 6 patiens(18.2%) experienced grade 3 and 4 hematological toxicities, respectively. Conclusion: Accelerated twice-daily radiotherapy by simultaneous integrate boosting combined with chemotherapy, might be an effective treatment for patients with limited-stage small cell lung cancer, and adverse-event rates were acceptable. We recommend that it be further confirmed by large sample prospective study.
Author Disclosure: M. Su: None. J. You: None. M. Song: None. L. Jiang: None.